PECAM-1 is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Breast Cancer
Abstract
Keywords
Full Text:
PDFReferences
Topalian, S.L., Drake, C.G., Pardoll, D.M.,: Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
Gumina, R.J., Kirschbaum, N.E., Rao, P.N., vanTuinen, P., Newman, P.J.,: The human PECAM1 gene maps to 17q23. Genomics 1996, 34:229-232.
Berman ME, Xie Y, Muller WA: Roles of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in natural killer cell transendothelial migration and beta 2 integrin activation. J Immunol 1996, 156:1515-1524.
Baldwin HS, Shen HM, Yan HC, DeLisser HM, Chung A, Mickanin C, Trask T, Kirschbaum NE, Newman PJ, Albelda SM, et al.: Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31): alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development 1994, 120:2539-2553.
Thompson RD, Noble KE, Larbi KY, Dewar A, Duncan GS, Mak TW, Nourshargh S: Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 2001, 97:1854-1860.
Prager E, Staffler G, Majdic O, Saemann M, Godar S, Zlabinger G, Stockinger H: Induction of hyporesponsiveness and impaired T lymphocyte activation by the CD31 receptor:ligand pathway in T.
DOI: http://dx.doi.org/10.18686/jn.v11i3.220
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Qingfang Yue, Yuan Zhang, Fei Cao, Fei Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.